Sutro Biopharma (STRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sutro Biopharma (STRO) has a cash flow conversion efficiency ratio of 0.438x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.19 Million) by net assets ($-87.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sutro Biopharma - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sutro Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sutro Biopharma debt and liabilities for a breakdown of total debt and financial obligations.
Sutro Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sutro Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ksolves India Limited
NSE:KSOLVES
|
0.016x |
|
Sandon Capital Investments Ltd
AU:SNC
|
0.061x |
|
HANSARD GLOBAL PLC LS-50
F:H9G
|
N/A |
|
Quality Construction Products Public Company Limited
BK:Q-CON
|
0.032x |
|
Hennessy Ad
NASDAQ:HNNA
|
0.007x |
|
BitNine Co. Ltd.
KQ:357880
|
-0.127x |
|
Advero Properties SOCIMI S.A.
MC:YADV
|
0.008x |
|
Horizon Space Acquisition II Corp. Ordinary share
NASDAQ:HSPT
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Sutro Biopharma (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sutro Biopharma from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see STRO company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $44.60 Million | $-191.54 Million | -4.295x | -475.79% |
| 2023-12-31 | $149.65 Million | $-111.62 Million | -0.746x | -4661.44% |
| 2022-12-31 | $217.05 Million | $3.55 Million | 0.016x | +105.06% |
| 2021-12-31 | $252.56 Million | $-81.68 Million | -0.323x | -58.38% |
| 2020-12-31 | $332.05 Million | $-67.80 Million | -0.204x | +69.29% |
| 2019-12-31 | $97.79 Million | $-65.02 Million | -0.665x | -789.62% |
| 2018-12-31 | $131.54 Million | $12.68 Million | 0.096x | -71.65% |
| 2017-12-31 | $-109.00 Million | $-37.07 Million | 0.340x | +135.06% |
| 2016-12-31 | $-90.90 Million | $-13.15 Million | 0.145x | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid … Read more